🌍 1. Regional Healthcare Landscape

The Middle East & North Africa (MENA) hosts over 220 million children—yet nearly 110 million live amid conflict zones, and every 5 seconds a child is displaced, maimed, or killed. These conflicts have devastated health systems, notably in Yemen and Syria, where destruction of medical facilities, interrupted services, and vaccine shortages are widespread .

Latin of child survival metrics show:

  • Maternal mortality halved from 220 to 110 per 100,000 (1990–2015); under‑5 mortality dropped 59%, now at ≈29 per 1,000
  • Vaccination gaps intensified: 4.3 million children missed measles shots during 2019–21; 3.8 million under‑vaccinated for DTP
  • Malnutrition is a triple threat: 10 million under‑5s stunted, 24 million acutely undernourished, and 55 million overweight or obese—totaling 77 million children affected WHO data finds 28% of children under 5 are stunted, 9% wasted, and underweight at 18%, while childhood obesity is on the rise—particularly among adolescents . Adult women also suffer: 40% are anaemic, 68% overweight or obese

🏗️ 2. Current Manufacturing Capacity & Approvals

Pakistan’s pharmaceutical footprint has grown markedly, with 40 companies showcasing surgical instruments, devices, disposables, and health-tech at Arab Health 2025 in Dubai—signaling ambition to access GCC and broader MENA markets. Yet, Pakistan remains over 90% dependent on imported raw materials, with local APIs at just ~12%. Regulatory mechanisms like DRAP offer a strong governance model, though MENA’s regulatory acceptance of Pakistani approvals varies country by country.

🩺 3. Opportunities for Taj Pharma

By leveraging Pakistan’s manufacturing agility and lower cost base, Taj Pharma can:

  • Expand essential medicines supply, particularly vaccines, micronutrient supplements, and maternal-child therapies—especially in underserved conflict zones.
  • Build local API facilities through partnerships and tech transfer, reducing reliance on imports.
  • Seek WHO pre‑qualification and align with Gulf Cooperation Council (GCC) regulations to enter lucrative markets across MENA.

👩‍👧 4. Social Impact: Women & Children’s Health

Improved access to high-quality, affordable healthcare products will have direct benefits:

  • Reduce maternal & infant mortality by 20–50% through better maternal nutrition, obstetric supplies, and clean childbirth interventions.
  • Reinforce vaccination campaigns, aiding catch-up efforts post-COVID to protect against measles, DTP, polio, cholera, etc.
  • Combat malnutrition with fortified food products and micronutrient supplements tailored for children and pregnant women.
  • Boost health for refugees and displaced populations, aligning with initiatives like UNRWA’s clinics and Caritas International’s humanitarian aid.

📊 5. Strategic Path Forward

Recommendations:

  1. Scale local production—focus on micronutrients, maternal-child drugs, vaccines, and clean birthing kits.
  2. Secure global certifications—WHO prequalification, GCC regulatory clearance, and approval from national registration authorities.
  3. Strengthen partnerships with UN agencies (UNICEF, UNRWA), NGOs (Caritas), and local health ministries for procurement deals.
  4. Enhance capacity via health-tech investment—digital records, telehealth, mobile clinics, and workforce training (as seen in Jordan) .

The MENA region stands at a critical healthcare crossroads. Despite strides in mortality reduction and immunization, conflict-driven disruption, malnutrition, and supply-chain fragility demand robust pharmaceutical intervention. Taj Pharma—armed with Pakistan’s manufacturing strengths—can play a transformative role: forging resilient supply lines, empowering vulnerable women and children, and contributing to a healthier, more stable future for MENA.

Sources: WHO, UNICEF, Arab Health, UNRWA, Caritas, Pakistan DRAP.

For More Info:

Contact: E-mail: info@tajpharma.com